期刊文献+

胃食管反流病中安慰剂反应率的相关研究

Study of Placebo Response Rate in the Treatment of Gastroesophageal Reflux Disease
原文传递
导出
摘要 目的:对胃食管反流病(GERD)随机对照试验中的安慰剂反应率进行Meta分析并研究影响该反应率的因素。方法:检索EMBASE,CochraneControlledTrialRegister和Medline数据库中公开发表的关于双盲、随机、安慰荆对照治疗GERD的英文文献,所有文献均包括质子泵抑制剂/H2受体阻滞剂,治疗时间至少为2周。对文献试验数据进行Meta分析,绘制森林图,同时绘制漏斗图检查发表偏倚。结果:纳入24个研究,共包括8917名患者。有效治疗的反应率与安慰剂反应率相比的OR为3.70(95%CI:2.77~4.95)。所有的安慰剂反应率为18.84%(2.93%-47.05%)。运用质子泵抑制剂治疗的患者与H:受体阻滞剂治疗者相比,安慰剂反应率明显降低(14.50%vs.24.68%,P=0.05)。糜烂性食管炎患者的安慰剂反应率与非糜烂性食管炎者相比略低,两者差异无显著性(P〉0.05)。结论:在GERD随机对照试验中,安慰剂反应率确实存在。该反应率降低与质子泵抑制剂的运用相关,而与腐蚀性食管炎的存在与否无关。 Objective: To perform a meta analysis of placebo response rate in randomized clinical trials of gastroesophageal reflux disease (GERD)and to investigate the influential factors of placebo response rate. Methods: The published English documents about randomized, double blind and placebo controlled trials of the treatment of GERD in Medline, Cochrane, Controlled Trial Register and EMBASE databases were searched. All these documents included proton-pump inhibitors or H2-receptor antagonists. The treatment duration was at least two weeks. Meta analysis was performed for the trial data in documents. The forest plot was drawn. Meanwhile, the funnel plot was drawn to determine the publication bias. Results: Twenty four studies with 8917 patients were enrolled. The odds ratio (OR) of the response rate of effective treatment to placebo response rate was 3.70 [95% CI:2.77 -4.95]. The overall placebo response rate was 18.84% (2.93%-47.05%). Compared with the patients treated by H2-receptor antagonists, the placebo response rate of patients treated by proton-pump inhibitors significantly decreased ( 14.50%vs.24.68% ,P=0.05 ). There was no significant difference in placebo response rate between patients with erosive esophagitis and patients with non-erosive esophagitis. Conclusion: The placebo response rate certainly exists in randomized controlled trials of GERD. The decreasing of the placebo response is related to the application of proton-pump inhibitors, hut has no association with erosive esophagitis.
出处 《现代生物医学进展》 CAS 2013年第25期4977-4980,共4页 Progress in Modern Biomedicine
关键词 安慰剂 胃食管反流 META分析 Placebos Gastroesophageal Reflux Meta Analysis
  • 相关文献

参考文献20

  • 1Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary [J]. Control Clin Trials, 1996,17(1):1-12.
  • 2Tack J. Is there a unifying role for visceral hypersensitivity and irritable bowel syndrome in nonerosive reflux disease [J]. Digestion,2008,78 (1):42-45.
  • 3Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the pro- ton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non erosive reflux disease [J]. Aliment Pharmacol Ther, 2009,29(12): 1261 - 1272.
  • 4Uemura N, Inokuchi H, Serizawa H, et al. EiTlcacy and safety of omeprazole in Japanese patients with nonerosive reflux disease [J]. J Gastroenterol, 2008,43(9):670-678.
  • 5Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a ran- domized placebo-controlled trial [J]. Am J Gastroenterol, 2005,100 (9):1914-1922.
  • 6Kahrilas P J, Miner P, Johansom J, et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease[J]. Dig Dis Sci, 2005,50(11):2009-2018.
  • 7Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heart- bum in patients without erosive oesophagitis [J]. Aliment Pharmacol Ther, 2003,18(9):875-882.
  • 8Johnsson F, Hatlebakk JG, Klintenberg AC, et al. Symptomrelieving effect of esomeprazole40 mg daily in patients with heartburn [J]. Scand J Gastroenterol, 2003,38(4):347-353.
  • 9Laheij R J, Van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylie acid associated upper gastrointestinal symptoms:a randomized placebo controlled trial[J]. Aliment Pharma- col Ther, 2003,18(1):109-115.
  • 10Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gatroesophageal reflux disease: a randomized placebo controlled trial [J]. Am J Gastroenterol, 2002,97(6): 1332-1339.

二级参考文献20

  • 1邹方明,庄则豪.胃食管反流病发病机制研究进展[J].中华临床医师杂志(电子版),2011,5(23):7035-7037. 被引量:13
  • 2陈吉,高美丽,崔宏,王忠.胃食管反流病与幽门螺杆菌感染的关系研究[J].国际消化病杂志,2006,26(5):360-361. 被引量:22
  • 3Matthew L Bechtold,Jason-Scott L Holly,Klaus Thaler,John B Marshall.Bravo (wireless) ambulatory esophageal pH monitoring: How do day 1 and day 2 results compare?[J].World Journal of Gastroenterology,2007,13(30):4091-4095. 被引量:4
  • 4Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease [ J]. Lan- cet, 2006, 367(9528): 2086-2100.
  • 5Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population [ J ]. J Gastroenterol, 2009, 44 (6) : 518-534.
  • 6Dent J, E1-Serag HB, Wallander MA, et al. Epidemiology of gastro- oesophageal reflux disease: a systematic review [ J]. Gut, 2005, 54 (5): 710-717.
  • 7Axon AT. Personal view : to treat or not to treat Helicobacter pylori and gastro-oesophageal reflux disease-an alternative hypothesis [ J]. Ali- ment Pharmacol Ther, 2004, 19(3) : 253-261.
  • 8Vakil N, van Zanten SV, Kahrilas P, et al. The montreal definition and classification of gastroesophageal reflux disease : a global evidence- based consensus paper [ J ]. Z Gastroenterol, 2007, 45 (11 ) :1225-1240.
  • 9Jones R, Junghord O, Dent J, et al. Development of the Gerd Q, a tool for the diagnosis and manayent of gastro-oesophageal reflux disease in primary care [ J ]. Aliment pharmacol Ther, 2009, 30 ( 10 ) : 1030-1038.
  • 10Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux dis- ease ( NERD)-acid reflux and symptom patterns [ J]. Aliment Phar- macol Ther, 2003, 17(4): 537-545.

共引文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部